Last updated: May 23, 2026
Sirturo (bedaquiline; Janssen) remains the core component of multidrug regimens for drug-resistant pulmonary tuberculosis (RR-TB and MDR-TB). Clinical development activity is concentrated in regimen optimization (duration, combinations, and use in special populations), while commercial trajectories track global DR-TB burden, treatment coverage, and payer adoption of guideline-concordant bedaquiline-containing regimens. Patent and regulatory exclusivity timing will determine the pace of generic and biosimilar-style competitive entries, but the immediate market risk is driven more by procurement dynamics and regimen competition than by near-term generic substitution.
What clinical trials are ongoing or recently completed for Sirturo (bedaquiline)?
Bedaquiline clinical trials are organized around three themes: (1) regimen efficacy and durability in RR/MDR-TB, (2) shortened and safer regimens, and (3) expanded access to populations such as pediatric patients and those with extrapulmonary disease.
Regimen-optimization trials: shorter, safer, more effective RR/MDR-TB regimens
Key trial designs in the bedaquiline program use bedaquiline in combinations with second-line agents (and, in some protocols, newer TB drugs) and evaluate culture conversion, time-to-cure, relapse, and safety endpoints such as QT prolongation.
Key efficacy and safety endpoints used across bedaquiline trials
Common endpoints across regimen studies include:
- Time to culture conversion and proportion culture negative at prespecified timepoints
- Relapse rates during follow-up
- Treatment success definitions used in DR-TB trials
- Cardiac safety metrics including QTcF changes and arrhythmia events
Pediatric and special-population studies: pediatric dosing, tolerability, and pharmacokinetics
Bedaquiline development has included pediatric-focused studies using weight-based dosing and pharmacokinetic evaluations to support label expansion.
Studies addressing combinations with TB new entrants
Protocols testing bedaquiline alongside other newer agents aim to improve regimen efficacy and reduce total duration while maintaining safety. These programs are typically paired with pharmacokinetic compatibility studies to ensure dosing does not compromise exposure.
How is Sirturo being used in clinical practice, and what regimen guidelines drive demand?
Demand for Sirturo is driven by uptake of bedaquiline-containing regimens in guideline-concordant MDR/RR-TB care. Clinical adoption depends on:
- Local diagnostic rates for DR-TB
- Availability of companion drugs in the regimen (to ensure multidrug coverage)
- National formulary inclusion and procurement volumes
- Clinician confidence based on cardiac safety monitoring practices
Key utilization drivers
- Diagnostic-to-treatment conversion for RR/MDR-TB
- Patient eligibility criteria and contraindication management (notably cardiac risk)
- Treatment duration choices and regimen switching decisions during therapy
Market-level implication
Because bedaquiline is used as part of a regimen rather than as a monotherapy, procurement and adoption are constrained by the availability of other regimen components and local program capacity for monitoring.
What is the current market size for Sirturo (bedaquiline), and what segments drive revenue?
Sirturo’s revenue is dominated by government and global public health procurement for MDR/RR-TB regimens. Segment drivers:
- Geographic concentration in countries with high DR-TB prevalence
- Program procurement cycles and forecast volatility
- Manufacturer tendering and national treatment program reforms
Revenue mix logic used by investors and procurement stakeholders
- Public-sector tenders and donor-supported programs typically dominate
- High-volume markets track DR-TB case detection and second-line regimen scale-up
- Uptake is influenced by national treatment guidelines and inclusion of bedaquiline in first-line DR-TB regimens
What market projections exist for Sirturo, and what assumptions are most sensitive?
Market projections for bedaquiline are sensitive to:
- Growth in DR-TB case detection and treatment initiation
- Country-level scale-up of guideline-concordant bedaquiline regimens
- Availability of diagnostics and companion drugs
- Pricing, tender terms, and channel mix between private and public procurement
- Competitive pressure from alternative regimen components (including other TB drug platforms) rather than from generic entry alone
Primary scenarios used in market modeling
High-growth scenarios assume:
- Faster scale-up of bedaquiline-containing regimens in high-burden countries
- Higher treatment success reducing discontinuation and re-treatment rates
- Continued procurement expansion through multilateral programs
Base scenarios assume:
- Steady adoption constrained by diagnostic coverage and regimen complexity
- Pricing pressure through tendering rather than sustained list price expansion
Downside scenarios assume:
- Slow DR-TB diagnostic expansion
- Procurement interruptions
- Treatment protocol changes that reduce bedaquiline exposure duration or shift it to narrower patient subgroups
When does Sirturo lose exclusivity in the US and Europe, and how does that affect generic entry?
Exclusivity timelines determine the theoretical entry window for generic bedaquiline tablets. The actual commercial inflection depends on whether regulators and payers switch to a generic product promptly after loss of exclusivity, and whether manufacturing and quality supply ramps quickly.
US regulatory exclusivity framework for small-molecule drugs
For a small-molecule drug, entry timing generally reflects:
- Composition-of-matter and method-of-use patent expirations
- FDA exclusivity protections (if applicable) such as Hatch-Wunsch-related exclusivities
- Any patent term adjustments and litigation-driven stays
Europe regulatory and patent framework
In the EU/UK, effective exclusivity timing reflects:
- Patent term, supplemental protection certificates (SPCs) if granted, and
- National validation and enforcement of specific patents
Generic entry risk mechanism
Generic entry is typically enabled by:
- Expiration of key Orange Book-listed patents (for the relevant NDA)
- Successful Paragraph IV certification and litigation outcomes (if any)
- Manufacturing and regulatory readiness to supply at scale
What patents protect Sirturo (bedaquiline), and how strong is the patent estate?
Bedaquiline’s patent estate typically includes:
- Composition-of-matter patents covering the active ingredient
- Crystalline forms (where claimed)
- Pharmaceutical formulations and dosage forms
- Methods of treatment for MDR/RR-TB regimens
Patent estate strength drivers
Patent strength is determined by:
- Claim breadth (compound, salts, polymorphs, formulation excipients)
- Number of listed patents still in force across core jurisdictions
- Expected claim construction durability under infringement scrutiny
- Litigation history and outcomes for the same patent family
Practical consequence
Even if composition-of-matter patents near expiration, formulation or method-of-use patents can delay substitution if they are Orange Book-listed and still enforced.
What is the Orange Book status of Sirturo in the US, and which patents are most important for challengers?
The Orange Book listing for Sirturo identifies patents tied to the NDA and associated exclusivity. For generic challengers, the most important are:
- Any patents listed that expire later than composition-of-matter
- Patents covering formulation and specific dosage forms
- Method-of-use patents that capture the approved regimen indications
How challengers structure Paragraph IV campaigns
Generic applicants typically target:
- The latest-expiring, most enforceable Orange Book patents in the NDA
- Patents that are easiest to design around (to reduce risk) while still achieving labeling alignment
Which companies are challenging Sirturo (bedaquiline), and what patent litigation affects the launch window?
For high-value TB drugs used in global public procurement, Paragraph IV challenges and litigation, if present, can drive:
- 30-month stays
- Design-around attempts
- Settlement agreements with generic entry-date conditions
Litigation impact categories
- Likelihood of an injunction (less common for small molecules used under ongoing procurement)
- Settlement triggering delayed launch
- Court invalidation reducing the estate
- Consent judgments formalizing carve-outs
What generic entry risks exist for Sirturo, and what is the probability of an accelerated launch?
Generic entry risk is a function of:
- Timing to expiration of the latest key patents
- Strength of infringement positions for the remaining listed claims
- Whether the NDA label is protected by method-of-use patents
- Supply chain capacity for bedaquiline tablets at scale
Probability logic used in competitive planning
- High probability: multiple late-expiring patents invalidated or settled with no launch delay; manufacturing readiness is high.
- Moderate probability: litigation prolongs entry or settlements add a launch date.
- Low probability: remaining enforceable method/formulation claims block labeling or trigger redesign.
How does Sirturo compare with alternative TB drugs or regimen platforms in commercial and clinical positioning?
Bedaquiline competes indirectly through regimen selection rather than by direct interchangeability with other TB agents. Clinical positioning depends on:
- Contribution to cure rates in MDR/RR-TB
- Safety monitoring requirements
- Compatibility with other regimen components
Competitive landscape comparison dimensions
- Evidence strength for MDR/RR-TB outcomes
- Safety profile and monitoring burden (cardiac monitoring)
- Duration impact on regimens (shortening potential)
- Procurement fit (tenderability and supply)
What formulations are protected for Sirturo, and what manufacturing/IP barriers could delay generics?
If Sirturo’s patent coverage includes:
- Formulation-specific claims (tablet composition, excipient systems, release characteristics)
- Crystalline or polymorphic form claims
- Specific manufacturing processes that are difficult to replicate
Then generics face barriers including:
- Higher development cost to match claimed physical form or dissolution behavior
- Additional bioequivalence challenges for reformulated products
- Legal risk if the design-around does not avoid literal claim coverage
What settlement agreements or licensing deals exist for Sirturo (bedaquiline), and how do they shape market timing?
Licensing or settlement structures in this segment commonly aim to:
- Resolve Paragraph IV disputes
- Define an agreed launch date
- Allocate regional rights or supply responsibilities
These agreements can materially shift the competitive landscape even when exclusivity timelines predict earlier entry.
How will patent expiration affect Sirturo pricing, tendering, and market share?
Once exclusivity ends, the expected pricing and share evolution in TB drugs is shaped by:
- Tender structures favoring low price
- Payer procurement switching speed
- Contracting frameworks and supply reliability
- Product interchangeability in treatment protocols
Expected post-exclusivity pattern
- Initial share retention if supply contracts are locked
- Rapid price pressure once generic-qualified supply scales
- Continued adoption if guidelines and pharmacovigilance support interchangeability
Key takeaways
- Sirturo’s clinical and commercial footprint is anchored in MDR/RR-TB regimen optimization, not stand-alone use.
- Market growth depends more on DR-TB detection and treatment scale-up than on near-term therapeutic switching.
- Exclusivity-driven generic substitution risk is determined by the latest Orange Book-listed patents and any litigation-driven stays or settlements.
- Post-exclusivity pricing and share changes will likely follow tender-driven procurement rather than immediate wholesale replacement.
FAQs
1) Do Sirturo trials include shortened regimens for MDR-TB, and what endpoints matter most?
Culture conversion timing, treatment success rates, relapse rates, and QT-related safety endpoints.
2) What drives Sirturo procurement in high-burden countries?
DR-TB diagnostic coverage, national treatment guideline adoption, tender award cycles, and regimen companion drug availability.
3) Which patent types most often delay generic entry for bedaquiline?
Method-of-use and formulation/dosage-form patents, especially when tied to Orange Book listings.
4) How do Paragraph IV challenges typically affect bedaquiline launch timing?
They can trigger a 30-month stay and settlement-based launch delays that override theoretical patent-expiration dates.
5) What safety monitoring requirements influence clinical uptake of Sirturo?
Cardiac monitoring practices related to QT prolongation risk and management protocols in DR-TB programs.
References
- US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Center for Drug Evaluation and Research (CDER).
- World Health Organization. Treatment of drug-resistant tuberculosis: guidelines and updates (latest editions).
- ClinicalTrials.gov. Search results for bedaquiline (Sirturo) and relevant combination studies.
- European Medicines Agency (EMA). EPAR for Sirturo (bedaquiline) and related assessment materials.
